Inmune Bio shares are trading lower after the company announced a $13 million registered direct offering of 2,341,260 shares.
Portfolio Pulse from Benzinga Newsdesk
Inmune Bio shares fell following the announcement of a $13 million registered direct offering of 2,341,260 shares.
September 13, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inmune Bio's stock price is negatively impacted by the announcement of a $13 million registered direct offering, which involves issuing 2,341,260 new shares.
The issuance of new shares typically dilutes existing shareholders' value, leading to a decrease in stock price. The $13 million offering suggests a need for capital, which can be perceived negatively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100